Inhibition of GH releasing factor (GRF)-induced GH secretion by intraruminal infusion of volatile fatty acids (VFA) in sheep.
A VFA mixture solution containing acetate, propionate and butyrate (the molar ratio of acetate, propionate and n-butyrate = 61.7:24.3:14.0) was infused into the rumen at various rates (53.5, 107 and 214 mumol kg-1 min-1) over 6 h to examine the effects on basal and growth hormone-releasing factor (GRF, 0.25 micrograms kg-1)-induced increase in secretion of GH, insulin, glucagon and somatostatin (SRIF) in five castrated male sheep. Intraruminal infusion of the VFA mixture into the 18-h-fasted animals at the rates of 53.5, 107 and 214 mumol kg-1 min-1 finally raised the total intraruminal VFA concentration from 91.4 to 100.2 (P > 0.05), 175.9 (P < 0.05) and 234.5 (P < 0.05) mmol l-1, respectively. A preliminary experiment showed that an infusion rate of 107 mumol kg-1 min-1 mimics the postprandial increase in ruminal VFA. The basal plasma GH concentrations (2 to 4 h after the start of VFA infusion) and the area under the profiles for GH release in response to the intravenous GRF injection, which was done 4 h after the start of VFA infusion, were significantly decreased by the VFA infusion rates of 107 and 214 mumol kg-1 min-1. Furthermore, the VFA infusion noticeably increased basal plasma concentrations of insulin, but it scarcely changed the basal levels of glucagon, SRIF and glucose. From these results we conclude that an increase in the ruminal VFA concentration, even within the physiological range, would suppress GH secretion from the ovine anterior pituitary, and that the postprandial rise in the ruminal VFA concentration may be one of the factors normally suppressing GH secretion in sheep.
Matsunaga
N
N
Department of Animal Physiology, Faculty of Agriculture, Tohoku University, Sendai, Japan.
Goka
T
T
Nam
K T
KT
Oda
S
S
Ohneda
A
A
Sasaki
Y
Y
D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005232:Fatty Acids, Volatile / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D005934:Glucagon / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D013006:Growth Hormone / Q000187:drug effects / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000187:drug effects / Q000494:pharmacology*; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood / Q000378:metabolism; D008297:Male; D012417:Rumen / Q000737:chemistry* / Q000378:metabolism; D012756:Sheep; D013004:Somatostatin / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D001786:Blood Glucose; D005232:Fatty Acids, Volatile; D007328:Insulin; D013004:Somatostatin; D013006:Growth Hormone; D005934:Glucagon; D013007:Growth Hormone-Releasing Hormone